DUBAI, UAE, 30 January 2024: Research (R&D) efforts must be rapidly localised to improve patient outcomes, deliver precision medicine, and catalyse scientific excellence as the UAE’s healthcare expenditure is projected to reach AED 112.7 billion by 2027, the findings of a new white paper by Dubai Science Park reveal.
Developed in collaboration with EY and engagements with 18 health system leaders and policymakers, Dubai Science Park’s The UAE Healthcare Ecosystem white paper explores global megatrends in the healthcare sector and their impact towards reshaping the ecosystem to accelerate personalised and precision medicine in the UAE.
The momentous shift towards digitally enabled healthcare is among the key findings of the paper, released on day one of the Arab Health exhibition, which runs from 29 January to 1 February in Dubai. With about 30% of the world’s entire data volume now generated by the healthcare industry, the paper explores how public and private sector investments are leveraging this asset to pioneer the integration of emerging technologies and enable novel therapy and personalised patient frameworks.
“Investing in localised research and initiatives is not only a scientific imperative, but a commitment to revolutionising healthcare for the greater good in the Middle East and beyond,” said Marwan Abdulaziz Janahi, Senior Vice President of Dubai Science Park at TECOM Group PJSC.
“Precision medicine represents a paradigm shift in the life sciences, and its diversion from a one-size-fits-all approach promises effective and targeted interventions, helping to fulfil the healthcare sector’s mission of patient-centricity. We are committed to championing awareness of these disruptive possibilities through ventures such as Dubai Science Park’s new white paper.”
Marwan Abdulaziz Janahi and Ahmed El Banna, Senior Manager of Healthcare Consulting at EY for the Middle East and North Africa region, launched the paper at a special Arab Health session. The paper explores the structural forces that impact healthcare in the UAE, where the sector’s GDP contribution is expected to remain above 4.3% between 2023 and 2027. Healthcare expenditure in the UAE grew by about 4% per year since 2016 to reach AED 79 billion in 2022, and is projected to further increase by 7% each year until 2027.
An important focus area for technologically powered future investments identified by the paper is genomic medicine and research, considered critical to improving drug design and delivering preventive and personalised medicine.
Also Read: Estonia’s Digital Health Triumph Shines at Arab Health 2024
Dubai Science Park’s white paper sheds light on the UAE’s Emirati Genome Programme, which aims to use genetic data to prevent and treat chronic and rare diseases. Information generated through the programme’s advanced sequencing technology, and analyses powered by artificial intelligence (AI), can curate genetic references that support advanced diagnosis for Emiratis and enable personalised healthcare and treatment pathways.
The white paper’s findings about the significance of localising healthcare R&D reiterate the overarching goals of the Dubai Research and Development Programme, according to Marwan Abdulaziz Janahi: “Strategic programmes like We the UAE 2031, Dubai Economic Agenda ‘D33’, and Dubai 2040 Urban Master Plan further empower co-creation between the public sector and industry champions and enable a pool of industry knowledge and talent, such as Dubai Science Park’s community of 450 customers and more than 5,500 professionals.”
Early findings from the paper’s review of sustainability in the UAE’s healthcare system were released at the COP28 conference in Dubai. Click here to download your copy of The UAE Healthcare Ecosystem white paper, presented during Dubai Science Park’s participation in the Arab Health exhibition.
In5 Science, a dedicated vertical launched by Dubai Science Park in collaboration with TECOM Group’s start-up incubator in June 2023, joins the event. Start-ups from in5 Science attending Arab Health include EMed Support Systems, utilizing AI for proactive cardiovascular management; KinesteX, an AI-powered provider of real-time form correction for remote workers; Neulink, automating operations and workflows for staff efficiencies; and Diagnio, offering home test systems to transform hormonal diagnostics for women.
TECOM Group is actively developing storage and logistics facilities with a gross leasable area of 200,000 sq.ft. at Dubai Science Park, enhancing the science district’s growth. The park is already home to industry leaders like AstraZeneca, BeiGene, Pfizer, and Virax Biolabs.
Furthermore, Dubai Science Park is part of TECOM Group’s portfolio of business districts that include Dubai Internet City, Dubai Media City, Dubai Studio City, Dubai Production City, Dubai Knowledge Park, Dubai International Academic City, Dubai Design District (d3), and Dubai Industrial City.
